Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Clinical experience with raloxifene].

J Szúcs1, I Pávó, N Jurida

  • 1I. Belgyógyászati Klinika, Semmelweis Orvostudományi Egyetem, Budapest.

Orvosi Hetilap
|March 4, 2000
PubMed
Summary

Selective estrogen receptor modulators (SERMs) like raloxifene offer tissue-specific effects, acting estrogen-like on bone and cardiovascular systems but anti-estrogenic in breast tissue. This review assesses raloxifene

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical profiles of post-load glucose subgroups and their association with glycaemic traits over time: An IMI-DIRECT study.

Diabetic medicine : a journal of the British Diabetic Association·2020
Same author

Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme.

Diabetic medicine : a journal of the British Diabetic Association·2018
Same author

Vitamin D and calcium supplementation for three years in postmenopausal osteoporosis significantly alters bone mineral and organic matrix quality.

Bone·2016
Same author

Bone quality of the newest bone formed after two years of teriparatide therapy in patients who were previously treatment-naïve or on long-term alendronate therapy.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2014
Same author

A mechanistic role for polypeptide hormone receptor lateral mobility in signal transduction.

Amino acids·2013
Same author

Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2010

Area of Science:

  • Pharmacology
  • Endocrinology
  • Oncology

Context:

  • Selective estrogen receptor modulators (SERMs) represent a class of drugs targeting estrogen receptors.
  • SERMs exhibit tissue-specific activity, mimicking estrogen in some tissues while blocking it in others.
  • Raloxifene is a notable SERM with a distinct profile, particularly its lack of estrogenic effects in the uterus.

Purpose:

  • To characterize the clinical features of raloxifene.
  • To evaluate the therapeutic potency of raloxifene based on recent clinical trials.

Summary:

  • Raloxifene, a selective estrogen receptor modulator (SERM), demonstrates estrogen-like effects on bone and cardiovascular health.
  • Conversely, it acts as an estrogen antagonist in mammary tissues, offering a potential therapeutic advantage.
  • Unlike some other SERMs, raloxifene does not induce estrogenic effects in the uterus, enhancing its safety profile.

Impact:

  • Provides a comprehensive overview of raloxifene's clinical applications.
  • Informs clinical decision-making regarding the use of raloxifene in postmenopausal women.
  • Highlights the therapeutic potential of SERMs in managing conditions like osteoporosis and reducing breast cancer risk.

Related Experiment Videos